A number of case reports or case series for neoadjuvant purposes have been published in different pathological types of thyroid cancer, such as BRAF V600E–mutated anaplastic thyroid carcinoma [21-23] and medullary thyroid cancer with RET mutation [24, 25]. Here, BRAF is linked to thyroid gland carcinoma.